Potential Drug Target and Biomarker for Parathyroid Hormone (PTH)

Target Name: PAH

NCBI ID: G5053

Content of Review Report on PAH Target / Biomarker

PAH

Potential Drug Target and Biomarker for Parathyroid Hormone (PTH)

Parathyroid Hormone (PTH) is a well-known hormone produced by the parathyroid gland that plays a crucial role in regulating calcium levels in the body. It is synthesized by the parathyroid gland filter, which is a small structure located at the base of each parathyroid gland. PTH is responsible for maintaining the proper levels of calcium in the blood, which is essential for various physiological functions, including muscle and nerve function, as well as bone development and maintenance.

Despite its importance, parathyroid hormone has been the subject of numerous scientific studies and is studied as a target in many drug studies. Parathyroid hormone has been found to be a potential drug target in the treatment of various diseases, including bone diseases, osteoporosis, and hyperparathyroidism.

One of the most promising research on PTH as a drug target is its potential to treat hyperparathyroidism, a condition in which the parathyroid gland produces too much PTH. Hyperparathyroidism is a disorder that can cause symptoms such as bone pain, increased thirst, and fatigue. Treatment of hyperparathyroidism is typically focused on reducing the production of PTH by the parathyroid gland, either through surgery or through the use of medications that inhibit the production of PTH.

Another potential use of PTH as a drug target is its potential to treat osteoporosis, a condition in which the bones become weak and fragile due to a loss of bone mass. Osteoporosis is a disease that can cause a significant loss of mobility and independence in older adults. Treatment of osteoporosis is typically focused on increasing bone density and reducing the risk of fractures.

PTH has also been shown to be a potential biomarker for the diagnosis and monitoring of various diseases, including osteoporosis and hyperparathyroidism. For example, studies have shown that PTH levels in individuals with osteoporosis are significantly lower than in individuals without the condition. Additionally, research has shown that PTH levels in individuals with hyperparathyroidism are often elevated compared to individuals without the condition.

In addition to its potential as a drug target and biomarker, PTH has also been found to have a number of potential therapeutic benefits. For example, PTH has been shown to have anti-inflammatory properties, which can be beneficial in reducing the risk of chronic pain. Additionally, PTH has been shown to have neuroprotective properties, which can be beneficial in reducing the risk of neurodegenerative diseases.

Overall, PTH is a fascinating molecule that has been studied extensively for its potential therapeutic benefits. Its potential as a drug target and biomarker make it an attractive target for research into the treatment of various diseases. Further research is needed to fully understand the potential of PTH as a therapeutic agent and to develop safe and effective treatments.

Protein Name: Phenylalanine Hydroxylase

Functions: Catalyzes the hydroxylation of L-phenylalanine to L-tyrosine

The "PAH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets